Literature DB >> 21613458

Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in mice.

Michael G Wallach1, Richard J Webby, Fakhrul Islam, Stephen Walkden-Brown, Eva Emmoth, Ricardo Feinstein, Kjell-Olov Gronvik.   

Abstract

Influenza viruses remain a major threat to global health due to their ability to undergo change through antigenic drift and antigenic shift. We postulated that avian IgY antibodies represent a low-cost, effective, and well-tolerated approach that can easily be scaled up to produce enormous quantities of protective antibodies. These IgY antibodies can be administered passively in humans (orally and intranasally) and can be used quickly and safely to help in the fight against an influenza pandemic. In this study, we raised IgY antibodies against H1N1, H3N2, and H5N1 influenza viruses. We demonstrated that, using whole inactivated viruses alone and in combination to immunize hens, we were able to induce a high level of anti-influenza virus IgY in the sera and eggs, which lasted for at least 2 months after two immunizations. Furthermore, we found that by use of in vitro assays to test for the ability of IgY to inhibit hemagglutination (HI test) and virus infectivity (serum neutralization test), IgYs inhibited the homologous as well as in some cases heterologous clades and strains of viruses. Using an in vivo mouse model system, we found that, when administered intranasally 1 h prior to infection, IgY to H5N1 protected 100% of the mice against lethal challenge with H5N1. Of particular interest was the finding that IgY to H5N1 cross-protected against A/Puerto Rico/8/34 (H1N1) both in vitro and in vivo. Based on our results, we conclude that anti-influenza virus IgY can be used to help prevent influenza virus infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613458      PMCID: PMC3147324          DOI: 10.1128/CVI.05075-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  15 in total

1.  Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines.

Authors:  Erich Hoffmann; Aleksandr S Lipatov; Richard J Webby; Elena A Govorkova; Robert G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-23       Impact factor: 11.205

2.  Oseltamivir resistance during treatment of influenza A (H5N1) infection.

Authors:  Menno D de Jong; Tan Thanh Tran; Huu Khanh Truong; Minh Hien Vo; Gavin J D Smith; Vinh Chau Nguyen; Van Cam Bach; Tu Qui Phan; Quang Ha Do; Yi Guan; J S Malik Peiris; Tinh Hien Tran; Jeremy Farrar
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

Authors:  Y Okuno; Y Isegawa; F Sasao; S Ueda
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

Review 4.  Chicken antibodies: a clinical chemistry perspective.

Authors:  D Carlander; J Stålberg; A Larsson
Journal:  Ups J Med Sci       Date:  1999       Impact factor: 2.384

Review 5.  Oral delivery of antibodies. Future pharmacokinetic trends.

Authors:  R M Reilly; R Domingo; J Sandhu
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

6.  Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice.

Authors:  Huan H Nguyen; Terrence M Tumpey; Hae-Jung Park; Young-Ho Byun; Linh D Tran; Van D Nguyen; Paul E Kilgore; Cecil Czerkinsky; Jacqueline M Katz; Baik Lin Seong; Jae Min Song; Young Bong Kim; Hoa T Do; Tung Nguyen; Cam V Nguyen
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

7.  Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study.

Authors:  Hans Kollberg; David Carlander; Hanne Olesen; Per-Erik Wejåker; Marie Johannesson; Anders Larsson
Journal:  Pediatr Pulmonol       Date:  2003-06

8.  Eimeria maxima gametocyte antigens: potential use in a subunit maternal vaccine against coccidiosis in chickens.

Authors:  M Wallach; N C Smith; M Petracca; C M Miller; J Eckert; R Braun
Journal:  Vaccine       Date:  1995-03       Impact factor: 3.641

9.  Prospects for universal influenza virus vaccine.

Authors:  Walter Gerhard; Krystyna Mozdzanowska; Darya Zharikova
Journal:  Emerg Infect Dis       Date:  2006-04       Impact factor: 6.883

10.  Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.

Authors:  Jiahai Lu; Zhongmin Guo; Xinghua Pan; Guoling Wang; Dingmei Zhang; Yanbin Li; Bingyan Tan; Liping Ouyang; Xinbing Yu
Journal:  Respir Res       Date:  2006-03-23
View more
  16 in total

1.  Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils.

Authors:  Kim Thomsen; Lars Christophersen; Peter Østrup Jensen; Thomas Bjarnsholt; Claus Moser; Niels Høiby
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

2.  Anti-Pseudomonas aeruginosa IgY Antibodies Induce Specific Bacterial Aggregation and Internalization in Human Polymorphonuclear Neutrophils.

Authors:  K Thomsen; L Christophersen; T Bjarnsholt; P Ø Jensen; C Moser; N Høiby
Journal:  Infect Immun       Date:  2015-04-20       Impact factor: 3.441

3.  A dual chicken IgY against rotavirus and norovirus.

Authors:  Ying-Chun Dai; Xu-Fu Zhang; Ming Tan; Pengwei Huang; Wen Lei; Hao Fang; Weiming Zhong; Xi Jiang
Journal:  Antiviral Res       Date:  2012-12-22       Impact factor: 5.970

4.  Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice.

Authors:  Hae-Jung Park; Boris Ferko; Young-Ho Byun; Joo-Hye Song; Gye-Yeong Han; Elisabeth Roethl; Andrej Egorov; Thomas Muster; Baiklin Seong; Mi-Na Kweon; Manki Song; Cecil Czerkinsky; Huan H Nguyen
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

5.  Monoclonal antibody specific to HA2 glycopeptide protects mice from H3N2 influenza virus infection.

Authors:  Xing Xie; Yan Lin; Maoda Pang; Yanbing Zhao; Dildar Hussain Kalhoro; Chengping Lu; Yongjie Liu
Journal:  Vet Res       Date:  2015-03-19       Impact factor: 3.683

6.  Immunotherapy with IgY Antibodies toward Outer Membrane Protein F Protects Burned Mice against Pseudomonas aeruginosa Infection.

Authors:  Fatemeh Norouzi; Bahador Behrouz; Mahya Ranjbar; Seyed Latif Mousavi Gargari
Journal:  J Immunol Res       Date:  2020-05-29       Impact factor: 4.818

7.  Immunotherapeutic Efficacy of IgY Antibodies Targeting the Full-Length Spike Protein in an Animal Model of Middle East Respiratory Syndrome Coronavirus Infection.

Authors:  Sherif A El-Kafrawy; Aymn T Abbas; Sayed S Sohrab; Ashraf A Tabll; Ahmed M Hassan; Naoko Iwata-Yoshikawa; Noriyo Nagata; Esam I Azhar
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-26

8.  Influenza Infection in Mice Induces Accumulation of Lung Mast Cells through the Recruitment and Maturation of Mast Cell Progenitors.

Authors:  Behdad Zarnegar; Erika Mendez-Enriquez; Annika Westin; Cecilia Söderberg; Joakim S Dahlin; Kjell-Olov Grönvik; Jenny Hallgren
Journal:  Front Immunol       Date:  2017-03-22       Impact factor: 7.561

Review 9.  IgY - turning the page toward passive immunization in COVID-19 infection (Review).

Authors:  Carolina Constantin; Monica Neagu; Teodora Diana Supeanu; Viorica Chiurciu; Demetrios A Spandidos
Journal:  Exp Ther Med       Date:  2020-04-30       Impact factor: 2.447

Review 10.  Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases.

Authors:  Lucia Lee; Kate Samardzic; Michael Wallach; Lyn R Frumkin; Daria Mochly-Rosen
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.